If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
48.50    0.00 (0.00%)
Bid:
48.00
Ask:
49.00
Spread: 1.00 (2.083%)
Market Cap: £7.38m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Board Changes

Today 07:00

RNS Number : 2289L
Transense Technologies PLC
07 July 2026
 

7 July 2026

Transense Technologies plc

("Transense" or the "Company")

Board Changes

Retirement of Chief Financial Officer and Appointment of Finance Director (designate)

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement solutions, announces that Melvyn Segal has informed the Board of his intention to retire from the role of Chief Financial Officer ("CFO") and Company Secretary with effect from the Company's Annual General Meeting (AGM) in November 2026. The Board also announces the appointment of Richard Michael Pearce ACA as Finance Director with effect from 1 September 2026.

Melvyn will remain with the Company in an executive capacity for a handover period until the AGM, and will subsequently remain on the Board as a non-executive director for a further year. The Board would like to thank Melvyn for his significant contribution to Transense over many years, during which the Company and its prospects have been transformed.

Richard brings over twenty years of financial, commercial and listed company experience to Transense. Since qualifying as a Chartered Accountant with Ernst & Young in 1999, he has held senior finance roles at GE Healthcare and TD Williamson, and most recently as Finance Director at Lombard Medical where he oversaw a scale-up in revenues from £6m to £25m per annum since 2018. He will initially work alongside Melvyn in a non-board role as Finance Director, with progression to the Board leading the Group's finance function when Melvyn's steps down as CFO in November 2026.

The Board welcomes Richard to his new role and we look forward to his contribution to delivery of the future growth strategy.

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Ryan Maughan (Managing Director)

Melvyn Segal (Chief Financial Officer)

Via Investor Relations

(see below)

Cavendish Capital Market Limited (Nominated Adviser and Broker)

Adrian Hadden / Callum Davidson (Corporate Finance)

Jasper Berry (Sales)

0207 220 0500

Investor Relations

Anice McNamee

Tel: +44 (0)1869 238380

Investor.relations@transense.co.uk

Notes to Editors:

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency, and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

· SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, automotive, and industrial machinery (including robotics), enabling improved efficiency and performance of their products. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied, Airbus and several other confidential Tier One automotive, aerospace and industrial machinery suppliers.

 

· Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. Enabling accurate measurement and digital capture of safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software.

 In addition, Transense earns residual royalty income from Bridgestone iTrack - a tyre monitoring system for off-highway vehicles that was developed by Translogik. The associated sales, support and development infrastructure were sold to Bridgestone Corporation, the world's largest tyre producer, in June 2020, and the intellectual property was licensed exclusively to Bridgestone under a ten-year deal expiring in 2030.

Find out more at: https://www.transense.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAAKABQCBKDDOK
Date   Source Headline
5th Jul 20227:00 amRNSYear End Trading Update
4th Jul 20227:00 amRNSSAW update - Appointment of Technical Director
21st Jun 202211:21 amRNSDirector/PDMR shareholding – acquisition of shares
31st May 20225:00 pmRNSTotal Voting Rights
27th May 20227:00 amRNSTransaction in own shares & TVR
26th May 20223:57 pmRNSHolding(s) in Company
24th May 20227:15 amRNSTransaction in own shares & TVR
19th May 20227:00 amRNSTransaction in Own Shares & TVR
17th May 20227:00 amRNSTRT wins place on TDAP & £135k Grant
16th May 20227:00 amRNSTransaction in Own Shares & TVR
11th May 20227:00 amRNSSAW Update
9th May 20227:00 amRNSTransaction in own shares & TVR
3rd May 20227:00 amRNSTransaction in own shares & TVR
26th Apr 20228:54 amRNSTransaction in Own Shares
19th Apr 20227:00 amRNSTransaction in Own Shares
2nd Mar 20225:15 pmRNSHolding(s) in Company
28th Feb 20227:00 amRNSDirector/PDMR - acquisition of shares
22nd Feb 20227:02 amRNSGrant of share options to employees
22nd Feb 20227:01 amRNSShare Repurchase Programme
22nd Feb 20227:00 amRNSInterim Results & Investor Presentation
31st Jan 20227:00 amRNSNotice of Results & Investor Presentation
23rd Dec 20212:51 pmRNSHolding(s) in Company
22nd Dec 20214:11 pmRNSDirector/PDMR Shareholding
7th Dec 20214:25 pmRNSDirector/PDMR Shareholding
30th Nov 20217:00 amRNSDirector/PDMR Shareholding - Acquisition of Shares
24th Nov 20217:00 amRNSDirector/PDMR shareholding – acquisition of shares
23rd Nov 202112:47 pmRNSResult of AGM
23rd Nov 20217:00 amRNSAGM Trading Update and Director Appointments
11th Nov 202111:40 amRNSHolding(s) in Company
2nd Nov 20217:01 amRNSAppointment of Additional SAWCAP Member
2nd Nov 20217:00 amRNSAGM Attendance & Investor Presentation
27th Oct 20217:00 amRNSAnnual Report, Notice of AGM & Investor Pres
4th Oct 20217:00 amRNSGrant of Options/PDMR Dealing
28th Sep 20217:00 amRNSFinal Results & Investor Presentation
14th Sep 20217:00 amRNS5 year JCA with McLaren Applied Ltd for SAW Tech
3rd Sep 20214:38 pmRNSHolding(s) in Company
31st Aug 20215:00 pmRNSTotal Voting Rights
26th Aug 20217:00 amRNSNotice of Annual Results & Investor Presentation
18th Aug 20213:30 pmRNSExercise of warrants
23rd Jul 20217:00 amRNSDirector/PDMR Shareholding
21st Jul 20217:00 amRNSNew member of Commercial Advisory Panel
5th Jul 20217:00 amRNSYear End Trading Update
2nd Jul 20211:12 pmRNSHolding(s) in Company
23rd Jun 20217:00 amRNSDirector/PDMR Shareholding
9th Apr 202110:05 amRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
19th Feb 20214:12 pmRNSHolding(s) in Company
18th Feb 20211:21 pmRNSDirector/PDMR shareholding
17th Feb 202110:34 amRNSDirector/PDMR shareholding
17th Feb 20217:00 amRNSInterim Results & Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.